Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel antibacterial class.

Peter J Dandliker1, Steve D Pratt, Angela M Nilius

  • 1Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA. peter.dandliker@abbott.com

Antimicrobial Agents and Chemotherapy
|November 26, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of simultaneous saccharification and fermentation with LPMO-supported hybrid hydrolysis and fermentation.

Frontiers in bioengineering and biotechnology·2024
Same author

The effects of free trade agreements on the stock market: Evidence from Vietnam.

PloS one·2024
Same author

The prospects of flexible natural gas-fired CCGT within a green taxonomy.

iScience·2023
Same author

Exploring new targets and chemical space with affinity selection-mass spectrometry.

Nature reviews. Chemistry·2023
Same author

Identification of immune-related molecular markers in intracranial aneurysm (IA) based on machine learning and cytoscape-cytohubba plug-in.

BMC genomic data·2023
Same author

Identification of circular RNAs expression pattern in caprine fetal fibroblast cells exposed to a chronic non-cytotoxic dose of graphene oxide-silver nanoparticle nanocomposites.

Frontiers in bioengineering and biotechnology·2023
Same journal

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy·2026
Same journal

Indole-based hybrids target both asexual parasites and gametocytes of <i>Plasmodium falciparum</i> and synergize with lumefantrine.

Antimicrobial agents and chemotherapy·2026
Same journal

Lineage-specific loss of the type VI secretion system in <i>Acinetobacter baumannii</i> ST19 is associated with reduced accessory genome content.

Antimicrobial agents and chemotherapy·2026
Same journal

Genomic diversity and topical antimicrobial resistance in <i>Staphylococcus aureus</i> from clinical and carriage populations in the New York-New Jersey region.

Antimicrobial agents and chemotherapy·2026
Same journal

Characterization of GUA-1, a chromosomally encoded ESBL from <i>Pseudomonas guariconensis-like</i>.

Antimicrobial agents and chemotherapy·2026
Same journal

A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistant <i>Acinetobacter baumannii</i>.

Antimicrobial agents and chemotherapy·2026
See all related articles
This summary is machine-generated.

Researchers discovered a new class of antibacterial compounds, novel ribosome inhibitors (NRIs), that effectively target drug-resistant respiratory pathogens. These NRIs show broad-spectrum activity and a unique mechanism of action, offering a promising new therapeutic option.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • The rise of antibiotic resistance necessitates the discovery of novel antibacterial agents.
  • Existing antibacterial classes face challenges due to resistance development.
  • Targeting bacterial protein synthesis remains a crucial strategy for developing new antibiotics.

Purpose of the Study:

  • To report the discovery and characterization of a novel class of ribosome inhibitors (NRIs).
  • To evaluate the antibacterial spectrum and mechanism of action of NRIs.
  • To assess the potential of NRIs as a new therapeutic class against drug-resistant pathogens.

Main Methods:

  • High-throughput screening of cell-free translation extracts from Streptococcus pneumoniae.
  • Chemical structure analysis and comparison with known antibacterial agents.

Related Experiment Videos

  • Expression array studies and analysis of resistant mutants to elucidate the mechanism of action.
  • Testing antibacterial activity against a panel of Gram-positive and Gram-negative bacteria, including common respiratory pathogens.

    • Main Results:

    • Discovery of a novel class of ribosome inhibitors (NRIs) with selective and broad-spectrum antibacterial activity.
    • NRIs inhibit the growth of key respiratory pathogens like Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis.
    • Compounds are nontoxic to human cell lines.
    • NRIs possess a distinct mechanism of action compared to quinolones and other known ribosome inhibitors, as evidenced by resistance studies.
    • Resistant strains show no cross-resistance to established antibiotic classes, indicating a novel inhibitory mechanism.

    Conclusions:

    • Novel ribosome inhibitors (NRIs) represent a promising new class of antibacterials.
    • NRIs exhibit potent activity against a wide range of bacteria, including major drug-resistant respiratory pathogens.
    • The unique mechanism of action suggests NRIs can overcome existing resistance pathways.
    • Further development of NRIs could provide a vital new tool in combating bacterial infections.